Literature DB >> 28600048

First trimester maternal serum analytes and second trimester uterine artery Doppler in the prediction of preeclampsia and fetal growth restriction.

Ning Yu1, Hongyan Cui2, Xu Chen2, Ying Chang2.   

Abstract

OBJECTIVE: This study aimed to determine whether pregnancy-associated plasma protein-A (PAPP-A), free β-human chorionic gonadotropin (β-hCG), a disintegrin and metalloprotease 12 (ADAM12), and placenta protein 13 (PP13) in the first trimester, and uterine artery Doppler (UAD) in the second trimester, predict preeclampsia and fetal growth restriction (FGR).
MATERIALS AND METHODS: Maternal serum levels of PAPP-A, free β-hCG, ADAM12, and PP13 at 11-13+6 weeks of gestation and bilateral uterine artery pulsatility index (PI) at 22-24 weeks of gestation were measured in a nested case-control study within a prospective cohort. The serum analytes and Doppler measurements were compared for uncomplicated pregnancies and pregnancies complicated by preeclampsia and FGR. The efficacy of biochemical and Doppler measurements for the prediction of preelampsia and FGR was investigated.
RESULTS: Compared with gestational age-matched controls (n = 200), the mean PAPP-A and ADAM12 were lower (P < 0.001, P < 0.05) in pregnancies complicated by preeclampsia (n = 462) and FGR (n = 350). The median uterine artery mean PI was higher (P < 0.001) in preeclampsia and FGR groups. However, the median free β-hCG and PP13 were not significantly different from normal (P > 0.05). In screening for preeclampsia and FGR, assuming a fixed false positive rate (FPR) of 10%, the detection rates were 72% and 68% for a combination of PAPP-A, ADAM12, and UAD, respectively.
CONCLUSION: First trimester PAPP-A and ADAM12 levels and second trimester uterine artery PI are associated with adverse pregnancy outcomes. The combination of biochemical markers and UAD improves the screening efficiency for the prediction of preeclampsia and FGR.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  ADAM12; Fetal growth restriction; PAPP-A; Preeclampsia; UAD

Mesh:

Substances:

Year:  2017        PMID: 28600048     DOI: 10.1016/j.tjog.2017.01.009

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  6 in total

1.  Does the Addition of Serum PAPP-A and β-hCG Improve the Predictive Value of Uterine Artery Pulsatility Index for Preeclampsia at 11-14 Weeks of Gestation? A Prospective Observational Study.

Authors:  Zeba Khanam; Pratima Mittal; Jyotsna Suri
Journal:  J Obstet Gynaecol India       Date:  2021-01-21

2.  Risk evaluation of fetal growth restriction by combined screening in early and mid-pregnancy.

Authors:  Bo Wang; Chunhua Zhang
Journal:  Pak J Med Sci       Date:  2020 Nov-Dec       Impact factor: 1.088

3.  Assessment of β-human-derived chorionic gonadotrophic hormone (βhCG) and pregnancy-associated plasma protein A (PAPP-A) levels as predictive factors of preeclampsia in the first trimester among Iranian women: a cohort study.

Authors:  Maryam Honarjoo; Shahnaz Kohan; Elahe Zarean; Mohammad Javad Tarrahi
Journal:  BMC Pregnancy Childbirth       Date:  2019-12-04       Impact factor: 3.007

Review 4.  A Systematic Review of the Safety of Blocking the IL-1 System in Human Pregnancy.

Authors:  Marie-Eve Brien; Virginie Gaudreault; Katia Hughes; Dexter J L Hayes; Alexander E P Heazell; Sylvie Girard
Journal:  J Clin Med       Date:  2021-12-31       Impact factor: 4.964

5.  Clinical Application of Multi-Index Combined Risk Assessment in Early Pregnancy for Screening of Preeclampsia.

Authors:  Xiaohong Xu; Guoxiu Yan; Jijun Liu; Xuelei Li; Bin Zhang; Xianglian Meng; Hongbo Chen; Baoliang Han; Kun Shao; Xuefen Zhao; Jing Liu; Yan Yan
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-27       Impact factor: 2.650

6.  Predictive Performance of Serum β-hCG MoM Levels for Preeclampsia Screening: A Meta-Analysis.

Authors:  Xiao Zhang; Zhao Huangfu; Fangxin Shi; Zhen Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-10       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.